South Africa has put its rollout of the Oxford-AstraZeneca vaccine on hold after a study showed “disappointing” results against its new Covid variant.
Scientists say the variant accounts for 90% of new Covid cases in South Africa.
The trial, involving some 2,000 people, found that the vaccine offered “minimal protection” against mild and moderate cases.
But experts are hopeful that the vaccine will still be effective at preventing severe cases.
South Africa has recorded almost 1.5 million coronavirus cases and more than 46,000 deaths since the pandemic began – a higher toll than any other country on the continent.
The country has received one million doses of the Oxford-AstraZeneca jab and was preparing to start vaccinating people.
“What we’re seeing from other vaccine developers is that they have a reduction in efficacy against some of the variant viruses and what that is looking like is that we may not be reducing the total number of cases, but there’s still protection in that case against deaths, hospitalisations and severe disease,” Prof Sarah Gilbert, Oxford’s lead vaccine developer, told the Andrew Marr Show on [February 7].
She said developers were likely to have a modified version of the injection against the South Africa variant, also known as 501.V2 or B.1.351, later this year.